ARID1A and head and neck cancer: Furthermore, in cancer cell lines from the CCLE database, the frequency of ARID1A damaging mutations ranged from 0%, for example for head and neck cancer cells, up to 62% (23 out of 37 cell lines have ARID1A mutations) for endometrial and uterine cancer cells (Table S1).